HealthTree Logo
search more_vert
person Sign In / Create Account
Relapsed/Refractory CLL Treatment Options with Dr. Kerry Rogers
Relapsed/Refractory CLL Treatment Options with Dr. Kerry Rogers image
Adult CLL Chapter
event Jun 25, 2024 / 01:00PM - 02:00PM EDT
Can't make it to the event?
We send a recording to all registered participants of the event!

Event Description

What treatment options do CLL patients have after venetoclax and covalent BTK inhibitors? Is the next treatment already FDA-approved, or is it administered in clinical trials? What is the best way for patients to navigate this decision-making process? Join the group discussion with Dr. Kerry Rogers, CLL specialist from the Ohio State University Comprehensive Cancer Center, to discuss this important topic! 

Schedule & Agenda

The panelist Megan Heaps
1:00 PM
Megan Heaps

Megan introduces the agenda of the event and featured speaker Dr. Kerry Rogers. 

The panelist Kerry Rogers, MD
1:05 PM
Kerry Rogers, MD

 Dr. Rogers shares insight about treatment options available to relapsed and refractory CLL patients. 

The panelist Audience
Questions and Answers
1:35 PM

Type your questions in the chat, and Dr. Rogers will answer them! 

Speakers & Moderators

The panelist Kerry Rogers, MD
Kerry Rogers, MD

Dr. Kerry Rogers is a hematologist-oncologist dedicated to advancing the care and treatment of patients with chronic lymphocytic leukemia (CLL) and autoimmune cytopenias. Following her initial medical education at Chicago Medical School, she completed her residency in internal medicine at the University of Michigan. She then undertook fellowship at The Ohio State University in hematology and oncology, and after completion of her training, she was delighted to join the staff at the OSUCCC – James. In addition to clinical work, she spends time teaching medical students and resident physicians as an assistant professor in the Department of Hematology. As a member of the Leukemia Research Program at the OSUCCC – James, she conducts research in the Experimental Hematology Laboratory developing novel therapeutics for autoimmune cytopenias. Her research group has an interest in finding optimal strategies for the use of BTK inhibitors, including studying resistance, combination therapies and treatment discontinuation. She is currently the principal investigator on four open and two pending clinical trials in this area, including two investigator-sponsored trials and an NCI study. She has also written several articles for publication in medical journals such as Leukemia and Cancer Cell, and has prepared numerous abstracts and posters for presentations. What she loves most about The James is working with very passionate and committed team members to give patients the very best care. She feels that communication is a key aspect to providing the best medical care and enjoys spending time with her patients most of all.

Read Bio
The panelist Megan Heaps
Megan Heaps

Megan joined HealthTree as the Program Manager for CLL in 2022. She is the daughter of a blood cancer patient and has found a passion for helping support patients and caregivers to advance research for their cure and improve their quality of life.

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.


Get In Touch With Us




Get the latest thought leadership on Chronic Lymphocytic Leukemia delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Chronic Lymphocytic Leukemia Newsletter" for Chronic Lymphocytic Leukemia news, life with Chronic Lymphocytic Leukemia stories, Chronic Lymphocytic Leukemia clinical trials, Chronic Lymphocytic Leukemia 101 articles and events with Chronic Lymphocytic Leukemia experts.

Thanks to our HealthTree Community for Chronic Lymphocytic Leukemia Sponsors:


Follow Us

facebook instagram youtube